
CYVADIC chemotherapy has also been used with LMS, and is an older combination.  It is a chemotherapy regimen composed of:
 
cyclophosphamide 
vincristine
adriamycin [doxorubicin] and 
dacarbazine [DTIC]

It will be toxic. Whether it has any advantage over adriamycin+dacarbazine alone, it will surely have more toxicity.

<b>Search Pubmed for &&url
Search Pubmed for &&url

Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.</b>
Cancer Treat Rep 1980 Jan;64(1):93-8 
Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS, Bodey GP.

"One hundred and forty adult patients with advanced sarcomas (125 soft tissue and 15 bone) were treated with ...(CYVADIC)." 

"There were 21 (15%) complete and 45 (32%) partial responders, with an overall response rate of 47%. The response rate was 50% (17% complete) for patients with soft tissue sarcomas compared with 20% (none complete) for patients with bone sarcomas. The median duration of response was 9.5 months (range, 1-40+ months) for complete responders and 7 months (range, 1-31 months) for partial responders." 

"The median time to achieve response was 9 weeks and the median number of courses of therapy to response was three. The median survival time was 16 months for responders compared with 7 months for nonresponders (P = 0.001). The most responsive tumor types were neurofibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, fibrosarcoma, and angiosarcoma. Pulmonary and soft tissue metastases were more responsive than bone and liver metastases. CYVADIC toxicity was predominantly limited to myelosuppression, vomiting, fever of unknown origin, and neuropathy. CYVADIC is an effective combination chemotherapy regimen in the treatment of advanced sarcomas."
&&url PMID: 7379060